BioCryst Pharmaceuticals, Inc. (BCRX)
8.015
-0.16
(-1.90%)
USD |
NASDAQ |
Oct 05, 10:13
BioCryst Pharmaceuticals Price : 8.015 for Oct. 5, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 02, 2026 | 8.12 | 8.20 | 7.92 | 8.17 | 6.149M |
| Oct 01, 2026 | 8.30 | 8.38 | 8.065 | 8.12 | 6.870M |
| Sep 30, 2026 | 8.28 | 8.42 | 8.184 | 8.33 | 13.10M |
| Sep 29, 2026 | 8.42 | 8.50 | 8.22 | 8.27 | 5.006M |
| Sep 28, 2026 | 8.555 | 8.66 | 8.335 | 8.47 | 4.355M |
| Sep 25, 2026 | 8.52 | 8.63 | 8.40 | 8.59 | 3.667M |
| Sep 24, 2026 | 8.535 | 8.65 | 8.395 | 8.52 | 4.854M |
| Sep 23, 2026 | 8.75 | 8.86 | 8.455 | 8.57 | 4.467M |
| Sep 22, 2026 | 8.87 | 9.035 | 8.72 | 8.78 | 3.442M |
| Sep 21, 2026 | 8.75 | 8.845 | 8.575 | 8.76 | 3.463M |
| Sep 18, 2026 | 8.60 | 8.835 | 8.492 | 8.68 | 12.75M |
| Sep 17, 2026 | 8.54 | 8.73 | 8.425 | 8.70 | 5.221M |
| Sep 16, 2026 | 8.15 | 8.45 | 8.11 | 8.43 | 5.860M |
| Sep 15, 2026 | 8.19 | 8.23 | 8.020 | 8.16 | 6.113M |
| Sep 14, 2026 | 8.17 | 8.38 | 8.095 | 8.23 | 5.097M |
| Sep 11, 2026 | 8.30 | 8.397 | 8.105 | 8.12 | 3.592M |
| Sep 10, 2026 | 8.34 | 8.46 | 8.045 | 8.29 | 9.001M |
| Sep 09, 2026 | 9.07 | 9.23 | 8.80 | 8.805 | 5.153M |
| Sep 08, 2026 | 9.122 | 9.40 | 8.96 | 9.065 | 9.688M |
| Sep 04, 2026 | 10.00 | 10.10 | 9.895 | 9.96 | 1.496M |
| Sep 03, 2026 | 10.15 | 10.22 | 9.935 | 10.09 | 1.974M |
| Sep 02, 2026 | 10.00 | 10.23 | 9.83 | 10.17 | 3.130M |
| Sep 01, 2026 | 9.72 | 9.955 | 9.63 | 9.92 | 3.367M |
| Aug 31, 2026 | 9.72 | 9.72 | 9.46 | 9.70 | 2.756M |
| Aug 28, 2026 | 9.822 | 9.96 | 9.72 | 9.82 | 2.703M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Amgen, Inc. | 400.86 |
| Halozyme Therapeutics, Inc. | 109.27 |
| Neurocrine Biosciences, Inc. | 143.82 |
| Vertex Pharmaceuticals, Inc. | 501.03 |
| Agenus, Inc. | 8.39 |
Price Related Metrics
| PS Ratio | 2.016 |
| PEG Ratio | -0.0070 |
| Price to Free Cash Flow | 5.324 |
| Earnings Yield | -18.76% |
| Market Cap | 2.046B |
| PEGY Ratio | -0.0070 |
| Operating PE Ratio | 4.932 |
| Normalized PE Ratio | 14.35 |